I spoke at a professional event for in-house General Counsels in the healthcare and pharma sectors, hosted by TopNet Network and GCs for GCs, on global and Israeli AI trends and their practical legal and strategic implications for companies operating in this ecosystem.
Main highlights (2026): Israel continues to stand out as a global AI powerhouse with approximately 2,300 AI companies, over 600 of them active in healthcare and medical AI. In December, Israel joined the U.S. led “Pax Silica” alliance, strengthening trusted access and collaboration across AI supply chains, from silicon to advanced models. AI is already reshaping healthcare and pharma, accelerating discovery, trials, diagnostics and personalization, while sharpening legal and strategic questions around regulation, liability, privacy, cybersecurity and transparency across Israel, the EU and the U.S.
Investors and acquirers now analyze AI in due diligence processes as a distinct area reviewing among other, governance, economics, controls, privacy and contractual constraints. AI alone no longer guarantees a valuation premium.
עיצוב ופיתוח - גבע בן ארי